Completely agree Rainman. There are 158m D’s listed worth over $70m to Imugene. That’s significant cash for any company. If we are sitting on the real deal, as many (including myself) believe we are, then there are 70 million reasons for IMU to announce information to the market to get the Ds in the money. This could be in the way of spectacular data or it could be commercial in nature - either way, the company undoubtedly has a looming date (31 Aug 2024) in the back of their mind.
I speculate that the latest MAST data cut to December 2023 is potentially an intentional decision by Imugene / trial organisers as they allow time for efficacious effects of CF33 Vaxinia to take hold. I wonder if rather than drip-feeding positive news, they are amassing compelling data for a more significant announcement. Something big to surely get the Ds across the line.
GLTAH, dyor.
IMU Price at posting:
9.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)